Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06971731 |
| Consolidated Lead Sponsor | Otsuka Pharmaceutical Development & Commercialization |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 120 participants (ESTIMATED) |
| Registered Start Date | 2025-10-20 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCLA Health and Jonsson Comprehensive Cancer Center | Los Angeles, CA | Open Hospital Dossier -> |
| University of South Florida | Tampa, FL | Open Hospital Dossier -> |
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | Open Hospital Dossier -> |
| Oregon Health and Science University Knight Cancer Institute | Portland, OR | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.